BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35711654)

  • 1. Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41.
    Yan H; Wu T; Chen Y; Jin H; Li L; Zhu Y; Chong H; He Y
    Front Cell Infect Microbiol; 2022; 12():916487. PubMed ID: 35711654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.
    Chen Y; Jin H; Tang X; Li L; Geng X; Zhu Y; Chong H; He Y
    Emerg Microbes Infect; 2022 Dec; 11(1):30-49. PubMed ID: 34821542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
    Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.
    Sun M; Pace CS; Yao X; Yu F; Padte NN; Huang Y; Seaman MS; Li Q; Ho DD
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):473-83. PubMed ID: 24853313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Chong H; Zhu Y; Yu D; He Y
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
    Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
    Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
    Moshoette T; Papathanasopoulos MA; Killick MA
    Virol J; 2022 Sep; 19(1):143. PubMed ID: 36071449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
    Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
    J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
    Yu D; Zhu Y; Yan H; Wu T; Chong H; He Y
    Emerg Microbes Infect; 2021 Dec; 10(1):810-821. PubMed ID: 33847245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.
    Pace CS; Song R; Ochsenbauer C; Andrews CD; Franco D; Yu J; Oren DA; Seaman MS; Ho DD
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13540-5. PubMed ID: 23878231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity.
    Borrego P; Calado R; Marcelino JM; Pereira P; Quintas A; Barroso H; Taveira N
    AIDS; 2013 Apr; 27(7):1081-90. PubMed ID: 23324659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.
    Song R; Pace C; Seaman MS; Fang Q; Sun M; Andrews CD; Wu A; Padte NN; Ho DD
    J Acquir Immune Defic Syndr; 2016 Dec; 73(4):365-373. PubMed ID: 27792681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.